NASDAQ:PTCTPTC Therapeutics Stock Price, Forecast & News

PTC Therapeutics' stock was trading at $47.08 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PTCT stock has increased by 1.6% and is now trading at $47.84. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for PTC Therapeutics.

PTC Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for PTC Therapeutics.

PTC Therapeutics, Inc. (NASDAQ:PTCT) announced its quarterly earnings results on Thursday, April, 30th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.00) by $0.81. The biopharmaceutical company had revenue of $68.30 million for the quarter, compared to analyst estimates of $81.90 million. PTC Therapeutics had a negative return on equity of 46.42% and a negative net margin of 90.83%. The business's revenue was up 26.5% on a year-over-year basis. During the same quarter last year, the firm posted ($1.29) earnings per share. View PTC Therapeutics' earnings history.

8 analysts have issued 1-year price targets for PTC Therapeutics' stock. Their forecasts range from $45.00 to $85.00. On average, they anticipate PTC Therapeutics' share price to reach $62.83 in the next year. This suggests a possible upside of 31.3% from the stock's current price. View analysts' price targets for PTC Therapeutics.

News coverage about PTCT stock has trended negative recently, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. PTC Therapeutics earned a coverage optimism score of -2.8 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the stock's share price in the near term. View the latest news aboutPTC Therapeutics.

Some companies that are related to PTC Therapeutics include Catalent (CTLT), Sarepta Therapeutics (SRPT), Ono Pharmaceutical (OPHLF), Horizon Therapeutics (HZNP), Mylan (MYL), Elanco Animal Health (ELAN), Dr.Reddy's Laboratories (RDY), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), ACADIA Pharmaceuticals (ACAD), Bausch Health Companies (BHC), Ascendis Pharma A/S (ASND), Jazz Pharmaceuticals (JAZZ), United Therapeutics (UTHR) and Myokardia (MYOK). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals PLC- (GWPH), Bausch Health Companies (BHC), Regulus Therapeutics (RGLS), NVIDIA (NVDA), Cisco Systems (CSCO), Aduro BioTech (ADRO) and Gilead Sciences (GILD).

PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."

PTC Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (9.92%), Franklin Resources Inc. (8.78%), BlackRock Inc. (8.17%), State Street Corp (3.77%), Janus Henderson Group PLC (2.81%) and Alliancebernstein L.P. (2.55%). Company insiders that own PTC Therapeutics stock include Allan Steven Jacobson, Christine Marie Utter, Emily Luisa Hill, Marcio Souza, Mark Elliott Boulding, Michael Schmertzler, Neil Gregory Almstead and Stuart Walter Peltz. View institutional ownership trends for PTC Therapeutics.

PTCT stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Bank of New York Mellon Corp, Federated Hermes Inc., Emerald Mutual Fund Advisers Trust, Pictet Asset Management Ltd., Emerald Advisers LLC, Morgan Stanley, and Morgan Stanley. Company insiders that have sold PTC Therapeutics company stock in the last year include Allan Steven Jacobson, Christine Marie Utter, Emily Luisa Hill, Marcio Souza, Mark Elliott Boulding, Neil Gregory Almstead, and Stuart Walter Peltz. View insider buying and selling activity for PTC Therapeutics.

PTCT stock was purchased by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Alliancebernstein L.P., TimesSquare Capital Management LLC, Janus Henderson Group PLC, BlackRock Inc., Redwood Investments LLC, International Biotechnology Trust PLC, and Invesco Ltd.. View insider buying and selling activity for PTC Therapeutics.

Shares of PTCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PTCT stock can currently be purchased for approximately $47.84.

PTC Therapeutics has a market capitalization of $3.01 billion and generates $306.98 million in revenue each year. The biopharmaceutical company earns $-251,580,000.00 in net income (profit) each year or ($3.45) on an earnings per share basis. PTC Therapeutics employs 511 workers across the globe.

The official website for PTC Therapeutics is www.ptcbio.com.

PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The biopharmaceutical company can be reached via phone at 908-222-7000 or via email at [email protected]